

WHO STEPS

Noncommunicable Disease

Risk Factor Survey

Data Book for country\_name

**survey\_year**

# Table of Contents

[Table of Contents 2](#_Toc184756197)

[1 Introduction 3](#_Toc184756198)

* ALL analyses use the variables **AgeRange**, **Sex**, and **Valid**.
* ALL weighted programs use the variables **PSU,** **Stratum,** and one of either **WStep1,** **WStep2,** or **WStep3**.
* Unweighted tables will not have confidence intervals associated with them.

# Introduction

|  |  |
| --- | --- |
| **Purpose of the data book** | This data book is a tool used to compile a complete set of data results relating to each question and measurement in the STEPS Instrument. The STEPS data book   * Provides detailed information for the data analyst on producing the results for the tables. * Provides examples of which tables to use in the country report. * Provides examples and suggestions on the layout of tables. |

|  |  |
| --- | --- |
| **Format of the data book** | Each page in the data book contains a different table with:   * Title and description of the table * Data tables for men, women and both sexes * Questions used to produce the table (actual question text) * Analysis information (Epi Info program name to produce the table). |

|  |  |
| --- | --- |
| **Global Action Plan 2013-2020 and Global Monitoring Framework** | STEPS captures 11 of the 25 indicators outlined in the Global Action Plan 2013-2020 and the Comprehensive Global Monitoring Framework for the Prevention and Control of NCDs[[1]](#footnote-1), relating to 7 of the 9 global targets.  Indicators captured in STEPS are marked in **bold** and *italic* in the table below. |

|  |  |
| --- | --- |
| **Tables in the data book relating to the Global Monitoring Framework** | Tables in the data book relating to the Global Monitoring Framework are identified with this symbol:  visue-gris-lNMH |

|  |  |  |
| --- | --- | --- |
| **Framework Element** | **Target** | **Indicator** |
| MORTALITY AND MORBIDITY | | |
| Premature mortality from noncommunicable disease | 1. A 25% relative reduction in the overall mortality from CVDs, cancer, diabetes, or chronic respiratory diseases | 1. Unconditional probability of dying between ages of 30 and 70 from cardiovascular diseases, cancer, diabetes or chronic respiratory diseases |
| Additional indicator | | 2. Cancer incidence, by type of cancer, per 100 000 population |
| BEHAVIOURAL RISK FACTORS | | |
| Harmful use of alcohol | 2. At least 10% relative reduction in the harmful use of alcohol, as appropriate, within the national context | 3. Total (recorded and unrecorded) alcohol per capita (aged 15+ years old) consumption within a calendar year in litres of pure alcohol, as appropriate, within the national context  ***4. Age-standardized prevalence of heavy episodic drinking among*** adolescents and ***adults***, as appropriate, within the national context  5. Alcohol-related morbidity and mortality among adolescents and adults, as appropriate, within the national context |
| Physical inactivity | 3. A 10% relative reduction in prevalence of insufficient physical activity | 6. Prevalence of insufficiently physically active adolescents, defined as less than 60 minutes of moderate to vigorous intensity activity daily  ***7. Age-standardized prevalence of insufficiently physically active persons aged 18+ years (defined as less than 150 minutes of moderate-intensity activity per week, or equivalent)*** |
| Salt/sodium intake | 4. A 30% relative reduction in mean population intake of salt/sodium | ***8. Age-standardized mean population intake of salt (sodium chloride) per day in grams in persons aged 18+ years*** |
| Tobacco use | 5. A 30% relative reduction in prevalence of current tobacco use | 9. Prevalence of current tobacco use among adolescents  ***10. Age-standardized prevalence of current tobacco use among persons aged 18+ years*** |
| BIOLOGICAL RISK FACTORS | | |
| Raised blood pressure | 6. A 25% relative reduction in the prevalence of raised blood pressure or contain the prevalence of raised blood pressure, according to national circumstances | ***11. Age-standardized prevalence of raised blood pressure among persons aged 18+ years (defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) and mean systolic blood pressure*** |
| Diabetes and obesity | 7. Halt the rise in diabetes & obesity | ***12. Age-standardized prevalence of raised blood glucose/diabetes among persons aged 18+ years (defined as fasting plasma glucose concentration ≥ 7.0 mmol/l (126 mg/dl) or on medication for raised blood glucose)***  13. Prevalence of overweight and obesity in adolescents (defined according to the WHO growth reference for school-aged children and adolescents, overweight – one standard deviation body mass index for age and sex, and obese – two standard deviations body mass index for age and sex)  ***14. Age-standardized prevalence of overweight and obesity in persons aged 18+ years (defined as body mass index ≥ 25 kg/m² for overweight and body mass index ≥ 30 kg/m² for obesity)*** |
| Additional indicators | | 15. Age-standardized mean proportion of total energy intake from saturated fatty acids in persons aged 18+ years  ***16. Age-standardized prevalence of persons (aged 18+ years) consuming less than five total servings (400 grams) of fruit and vegetables per day***  ***17. Age-standardized prevalence of raised total cholesterol among persons aged 18+ years (defined as total cholesterol ≥5.0 mmol/l or 190 mg/dl); and mean total cholesterol concentration*** |

|  |  |  |
| --- | --- | --- |
| **Framework Element** | **Target** | **Indicator** |
| NATIONAL SYSTEMS RESPONSE | | |
| Drug therapy to prevent heart attacks and strokes | 8. At least 50% of eligible people receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes | ***18. Proportion of eligible persons (defined as aged 40 years and older with a 10-year cardiovascular risk ≥30%, including those with existing cardiovascular disease) receiving drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes*** |
| Essential noncommunicable disease medicines and basic technologies to treat major noncommunicable diseases | 9. An 80% availability of the affordable basic technologies and essential medicines, including generics required to treat major noncommunicable diseases in both public and private facilities | 19. Availability and affordability of quality, safe and efficacious essential noncommunicable disease medicines, including generics, and basic technologies in both public and private facilities |
| Additional indicators | | 20. Access to palliative care assessed by morphine-equivalent  21. Adoption of national policies that limit saturated fatty acids and virtually eliminate partially hydrogenated vegetable oils in the food supply, as appropriate, within the national context and national programmes  22. Availability, as appropriate, if cost-effective and affordable, of vaccines against human papillomavirus, according to national programmes and policies  23. Policies to reduce the impact on children of marketing of foods and non-alcoholic beverages high in saturated fats, trans fatty acids, free sugars, or salt  24. Vaccination coverage against hepatitis B virus monitored by number of third doses of Hep-B vaccine (HepB3) administered to infants  ***25. Proportion of women between the ages of 30–49 screened for cervical cancer at least once, or more often, and for lower or higher age groups according to national programmes or policies*** |

1. World Health Organization. Global action plan for the prevention and control of NCDs 2013-2020. Geneva: World Health Organization; 2013. [↑](#footnote-ref-1)